Tekmira Pharmaceuticals Corp.’s development of a treatment for the Ebola virus has suffered a setback, as researchers halted enrollment in a clinical trial in Sierra Leone, after finding the drug wasn’t helping infected patients.
WSJ.com: What's News Europe, Wall Street Journal: What's News Europe
Fri, 06/19/2015 - 9:57am
Tekmira Pharmaceuticals Corp.’s development of a treatment for the Ebola virus has suffered a setback, as researchers halted enrollment in a clinical trial in Sierra Leone, after finding the drug wasn’t helping infected patients.